Parkinson's Incidence Cohorts Collaboration (PICC)

Parkinson's Incidence Cohorts Collaboration (PICC)

Parkinson's Incidence Cohorts CollaborationAn international collaboration of six population-based Parkinson's disease incidence cohorts in Northern Europe, which provides a unique opportunity for investigating the prognosis/disease progression of Parkinson's.

 

Parkinson's Incidence Cohorts Collaboration (PICC)

Why study prognosis in Parkinson's?

Robust data about prognosis (disease progression) is important for many reasons, including to:

  • Inform people with Parkinson's and their relatives how they may be affected over time
  • Identify factors which influence prognosis and modify them to improve prognosis where possible
  • Enhance clinical trial design and make them more efficient
  • Enable personalised medicine – tailored treatment according to an individual's estimated prognosis
Why incidence cohorts?

Most studies of prognosis in Parkinson's have been derived from specialist clinics resulting in cohorts which under-represent the old and frail. This leads to selection bias and results in over-optimistic estimates of overall prognosis.

Incidence cohorts begin by identifying all new cases of Parkinson's in a population in a defined time period (an incidence study) and follow-up these participants over time.

By attempting to recruit and follow-up all new cases of Parkinson's in the population, selection bias should be low and the cohort should be representative of the population with Parkinson's. This results in more reliable estimates of prognosis than other study designs

PICC Studies

The cohorts of the PICC study are based at the Univeristy of Aberdeen, the University of Bergen, the University of Cambridge, Newcastle University, the University of Stavanger, and Umeå University.

University of Aberdeen logoUniversity of CambridgeNewcastle UniversityUmea UniversityUniversity of BergenNKB

Information regarding each cohort can be found at:

Table 1: Characteristics of studies included in the Parkinson’s Incidence Cohorts Collaboration

Study CamPaIGN ICICLE-PD NYPUM ParkWest PICNICS PINE Pooled
cohort
Location Cambridgeshire UK Newcastle/
Gateshead UK
Umeå, Sweden Western Norway Cambridgeshire
UK
Aberdeen
UK
Northern Europe
Recruitment Period 2000-2 2009-11 2004-9 2004-6 2008-10 2002-4;
2006-9
2000-2011
Consent to follow-up amongst incident population 79% 48% 94% 79% 74% 94% 78%
Cases in analysis 141 82 + 72* 144 191 123 + 155* 201 882 + 227*
Median follow-up in years 8.9 6.6 10.0 7.2 5.0 12.1 7.3
Max follow- up of data in PICC database in years 10 8 13 8 9 16 16
Cases of dementia/death 41/63 21/18 60/77 46/34 31/21 89/149 298/362

*Additional cases in ICICLE-PD and PICNICS are Inception cases but not true incidence cases, i.e. not part of the incidence study.

Follow-up durations and cases of dementia/death refer to the 2021 update of the PICC database.

What data are available?
  • Demographics, e.g. age, sex, ethnicity, education, smoking status
  • Genetic: including APOE, GBA, MAPT, SNCA
  • Hoehn &Yahr stage
  • Impairment: UPDRS or MDS-UPDRS
  • Cognitive: MMSE
  • Dopaminergic treatment variables
  • Activities of daily living: Schwab & England
  • Quality of life: PDQ39
  • Key clinical outcomes: functional dependency, dementia, institutionalisation, death.
Members of Steering Group
  • Carl Counsell (chair), Angus Macleod (University of Aberdeen, UK)
  • Ole-Bjørn Tysnes (Haukeland University Hospital, Norway)
  • Caroline Williams-Gray, Marta Camacho (University of Cambridge, UK)
  • Rachael Lawson, Alison Yarnall (Newcastle University, UK)
  • Guido Alves, Jodi Maple-Grødem (Stavanger University Hospital, Norway)
  • Lars Forsgren, David Bäckström (Umeå University)
Publications

Szwedo AA, Dalen I, Pedersen KF, Camacho M, Bäckström D, Forsgren L, Tzoulis C, Winder-Rhodes S, Hudson G, Liu G, Scherzer CR, Lawson RA, Yarnall AJ, Williams-Gray CH, Macleod AD, Counsell CE, Tysnes OB, Alves G, Maple-Grødem J; Parkinson's Incidence Cohorts Collaboration. GBA and APOE Impact Cognitive Decline in Parkinson's disease: A 10-Year Population-Based Study. Mov Disord. 2022;37(5):1016-27.

Camacho, M., MacLeod, A., Maple-Grødem, J., Evans, J., Breen, D., Cummings, G., Wijeyekoon, R., Greenland, J., Alves, G., Tysnes, O., Lawson, R., Barker, R. A., Williams-Gray, C.. Early constipation predicts faster dementia onset in Parkinson's disease. NPJ Parkinson's Disease 2021; 7: 45.

Ramsay N, Macleod AD, Alves G, et al. Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease. Parkinsonism & Related Disorders 2020; 76: 49-53.

Funders

PICC has been funded by the Chief Scientist Office of the Scottish Government, the Academy of Medical Sciences, NHS Grampian Endowments, and Parkinson’s UK.

Chief Scientist Office  The Academy of Medical Sciiences  NHS Grampian - endowment fund - making a difference  Parkinson's UK - Change Attitudes. Find Cure. Join Us.

Nasjonalforeningen for folkehelsen logo

We are also grateful to the funders who have suppported each study included in PICC, full details of which can be found at each cohort’s homepage.